Infliximab (IFX) is potentially immunogenic, causing anti-infliximab antibodies that may interfere with the clinical efficacy and safety of the drug. There is an industry in measuring these antibodies, but the technicalities are legion, association with response poor and if they affect pharmacokinetics, it is by influencing drug levels. In contrast, IFX levels are associated with clinical response. So why make it complex? In this paper, we evaluate studies reporting the incidence of IFX antibodies in IBD, their impact on efficacy, safety and pharmacokinetics of IFX.
Journal article
Practical Gastroenterology
01/10/2010
34
11 - 20